Clinical trials: HIV-DDI
HIV Infections
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
To determine the safety, toxicity, pharmacokinetic profile, and antiretroviral activity of atevirdine mesylate ( U-87201E ) in HIV-infected patients.
- Trial name
- NCT00000753
- Testing
- Atevirdine mesylate, Zidovudine, Zalcitabine
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Combination Drug Treatment of Pediatric HIV Infection
This study will test the safety and effectiveness of hydroxyurea, an anti-cancer drug, given together with the anti-HIV drugs didanosine, stavudine and efavirenz for treating children infected with human immunodeficiency virus…
- Trial name
- NCT00001818
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir [ABC] plus efavirenz [EFV] plus didanosine [ddI]) with and without hydroxyurea (HU).
- Trial name
- NCT00005018
- Testing
- Hydroxyurea, Abacavir sulfate, Efavirenz
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Glaxo Wellcome
HIV Infections
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment.
- Trial name
- NCT00000902
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 217 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Disease Progression and Anti-HIV Treatments
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen.
- Trial name
- NCT00001068
- Testing
- Lamivudine
- Where
- 41 sites in United States, Puerto Rico and 1 more
- Volunteers
- 210 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Comparison of ddI Versus Zidovudine in HIV-Infected Patients
To compare the effectiveness and toxicity of didanosine (ddI) and zidovudine (AZT) in patients with AIDS, advanced AIDS-related complex (ARC), or asymptomatic infection with CD4 counts < 200 cells/mm3.
- Trial name
- NCT00000979
- Testing
- Zidovudine, Didanosine
- Where
- 71 sites in United States, Puerto Rico
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluation of Patients Who Have Not Had Success With Zidovudine
To determine the relationship of viral susceptibility to zidovudine (AZT) and baseline viral load (as determined by plasma viremia and quantitative endpoint dilution).
- Trial name
- NCT00001025
- Testing
- Zidovudine, Didanosine
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
To compare the antiviral activity, safety, toxicity, and steady-state pharmacokinetics of zidovudine, didanosine, and nevirapine used in combination in patients with HIV infection.
- Trial name
- NCT00000814
- Testing
- Nevirapine, Zidovudine, Didanosine
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 390 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women
To assess the pharmacokinetics, safety, and toxicity of intravenous and oral didanosine (ddI) administration in third trimester pregnant women who are HIV positive but are either intolerant or resistant to zidovudine (AZT).
- Trial name
- NCT00000839
- Testing
- Didanosine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
To assess the safety and toxicity of zidovudine (AZT)/didanosine (ddI) versus AZT/ddI combined with nevirapine in HIV-infected patients, and to obtain preliminary anti-HIV activity data using immunologic and virologic markers.
- Trial name
- NCT00000770
- Testing
- Nevirapine, Zidovudine, Didanosine
- Where
- 44 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
To assess the safety and tolerance of the combination of zidovudine (AZT) and didanosine (ddI) in children with HIV infection. New approaches to using available agents may provide increased or improved treatment options for AIDS.
- Trial name
- NCT00000652
- Testing
- Zidovudine, Didanosine
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past
To compare the efficacy, safety and tolerance, and other clinical and immunologic effects of zidovudine (AZT) plus zalcitabine (dideoxycytidine; ddC), AZT plus didanosine (ddI), and AZT alternating monthly with ddI as measured by…
- Trial name
- NCT00001029
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 37 sites in United States, Puerto Rico and 1 more
- Volunteers
- 654 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children
To evaluate the safety and determine the pharmacokinetic disposition of stavudine (d4T) alone and in combination with didanosine (ddI), and whether concurrent administration alters the disposition of either drug.
- Trial name
- NCT00000851
- Testing
- Stavudine, Didanosine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 198 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs.
- Trial name
- NCT00002168
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
AIDS Dementia Complex, HIV Infections
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
To compare the safety and effectiveness of orally administered didanosine (ddI) with high dose orally administered zidovudine (AZT) in patients who develop or exhibit progression of the AIDS dementia complex (ADC) and who have…
- Trial name
- NCT00000657
- Testing
- Zidovudine, Didanosine
- Where
- 13 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
The primary purpose of this study is to find the dose of Efavirenz for young children. The safety and how the medication is tolerated will also be studied.
- Trial name
- NCT00364793
- Testing
- Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
- Where
- 17 sites in Argentina, Colombia and 4 more
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
To assess the safety and to evaluate the anti-HIV effect of low-, moderate-, and high-dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone in asymptomatic HIV-infected patients.
- Trial name
- NCT00000656
- Testing
- Zidovudine, Didanosine
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
The purpose of this study is to find out whether or not the addition of hydroxyurea to didanosine (ddI) and other anti-HIV medications will result in better control of HIV infection.
- Trial name
- NCT00008866
- Testing
- Tetanus Toxoid Vaccine, Hydroxyurea, Didanosine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior…
- Trial name
- NCT00000838
- Testing
- Lamivudine, Stavudine, Zidovudine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 256 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV
To determine the pharmacokinetics, safety, and efficacy of didanosine (ddI) alone or in combination with zidovudine (AZT) in HIV-infected infants. PER AMENDMENT 4/8/97: Part A study objectives are completed.
- Trial name
- NCT00001049
- Testing
- Zidovudine, Didanosine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)